Search results

Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

Result type

Technology appraisal guidance

Published

9 June 2021

Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.

Result type

Technology appraisal guidance

Published

5 October 2022

Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.

Result type

Technology appraisal guidance

Published

4 January 2023

In development [GID-TA11247] Expected publication date: 30 July 2025

Result type

Technology appraisal guidance

Status

In development

This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

Result type

NICE guideline

Published

3 May 2019

Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

Result type

Technology appraisal guidance

Published

2 February 2022